Right BACH2 at you @roychoudhurilab.bsky.social 😆 Fantastic to see research on BACH2 from former #ListerFellow Rahul Roychoudhuri and colleagues included in Nature News and Views. Read the paper on fine-tuning BACH2 dosage to enhance antitumor T cell therapy⤵️ www.nature.com/articles/s41...

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - Nature Immunology

One of three back-to-back papers to show dosage of BACH2 can modulate T cell differentiation and function and how we might apply this to enhance chimeric antigen receptor T cell therapies for cancer.

nature.com

Roychoudhuri Lab@roychoudhurilab.bsky.social · 5mo ago

Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com Love the title: BACH2 the future! www.nature.com/articles/s41...

A compelling shift toward tissue-centric immunity: lymphoid niches don’t just initiate responses—they time and constrain them. Brilliant now work from Lukas Altenberger shows that timing of initiating and terminating immune response are equally important. www.science.org/doi/10.1126/...

Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality

The generation of effector CD8+ T cells (TEFF) requires activation of naïve CCR7+ T cells (TN) by dendritic cells (DCs) in lymphoid tissue. How TN-DC interaction duration and signal integration are co...

science.org

Incredible paper from Max Krummel's lab showing macrophages can sample cellular content from living cells for presentation to T cells pubmed.ncbi.nlm.nih.gov/42056510/

Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com Love the title: BACH2 the future! www.nature.com/articles/s41...

Great News & Views piece on the three BACH2 dosing papers recently published in @natimmunol.nature.com Love the title.. BACH2 the future! www.nature.com/articles/s41...

Immunoinformatics is revolutionising our understanding of cancer immunology and immunotherapy responses. If anyone is interested in joining our lab through this fellowship, I'd be very keen to support an application - do get in touch! www.cancerresearch.org/immuno-infor...

A great piece in ACIR discussing the there papers on #BACH2 dosing for T cell therapy of cancer recently out in @NatImmunol bit.ly/3atHQyV

Roychoudhuri Lab@roychoudhurilab.bsky.social · 6mo ago

Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...

Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...

Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial - Nature Medicine

In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...

nature.com

We have an active search for tenure-track faculty interested in #ImmuneEngineering #ProteinEngineering #GenomeEngineering & #CancerImmunology. Join the newly formed Center for Cellular Therapies and Cancer Immunology #CCTCI. Learn more at apply.interfolio.com/173562. #facultyjobs

Great to see this out, it was fun to work with Roychoudhuri lab on this really nice story. A good illustration that too much "stemness" in T cells can be a bad thing.

Roychoudhuri Lab@roychoudhurilab.bsky.social · 7mo ago

Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...

Unraveling CD8 lineage decisions reveals that functionally distinct CD8+ T cells are selected by different MHC-I thymic peptides @natimmunol.nature.com www.nature.com/articles/s41...

The paper is part of three parallel submissions from the labs of Nathan Singh & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer. @Cambridge_Uni @CRUKCambridge

New study suggests that metastatic cancer cells may evade the immune system by stealing mitochondria from immune cells and setting up a ‘shield’ that protects them from being killed by immune cells. Wiley little bastards. #Science 🧪

Cancer might evade immune defences by stealing mitochondria

Hijacking the energy-producing organelles from immune cells seems to help tumours in mice to infiltrate lymph nodes.

nature.com

"It’s exciting to think that the new therapy that helped me might be able to save other people, too," says JC Cox. He was only the eighth person at MD Anderson to be treated with CAR NK cells. Read his story: spr.ly/63326C03Jo #OncSky #EndCancer

CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission  

Non-Hodgkin lymphoma survivor JC Cox turned to MD Anderson when local treatment failed to keep the cancer at bay. Here, a single dose of a novel cell therapy administered through a clinical trial has put — and kept — him in remission.

spr.ly

Terribly uncanny how relevant this is to today.

In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo. https://www.nature.com/articles/s41591-025-04090-y

Super cool..

Science Magazine@science.org · 7mo ago

In a new Science study, researchers introduce DrugCLIP, a contrastive learning framework that virtually screens small molecules and protein pockets, analyzing protein-ligand interactions 10 million times faster than most standard molecular docking approaches. https://scim.ag/45FfSj2

Thanks Jaehyuk.. hope all is well

Jaehyuk Choi@jaehyukchoimd.bsky.social · 7mo ago

Congratulations!

Wonderful to collaborate with you on this Ian and enormous thanks to Christian, Shienny and Nicole for the heavy lifting!

Ian Parish@ianparish.bsky.social · 7mo ago

Great to see this out, it was fun to work with Roychoudhuri lab on this really nice story. A good illustration that too much "stemness" in T cells can be a bad thing.

BACH2 dosage balances stemness & effector functions of antitumor T & CAR-T @natimmunol.nature.com @roychoudhurilab.bsky.social @ianparish.bsky.social @washumedicine.bsky.social @utswim.bsky.social www.nature.com/articles/s41... www.nature.com/articles/s41... www.nature.com/articles/s41...

Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...

Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...

Fantastic overview of mechanisms by which low-dose #Aspirin exerts prevents #metastasis in cancer www.nejm.org/doi/full/10....

Understanding How Aspirin Prevents Metastasis | NEJM

A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.

nejm.org

📢 Don’t miss the last Cancer Biology and Medicine talk of 2025 tomorrow! Cancer immunology and immunotherapy Prof Rahul Roychoudhuri @campathology.bsky.social 📅 Thurs 11 December, 9:30-10:30 📍Theo Chalmers lecture theatre, School of Clinical Medicine All welcome! @cambridge-scm.bsky.social

Catz researchers teach old drugs new tricks: @roychoudhurilab.bsky.social (2020) on how aspirin could prevent some cancers from spreading: www.caths.cam.ac.uk/... PhD work by Felicity Crawshay-Williams led to the identification of new combinations of existing antibiotics: www.caths.cam.ac.uk/...

We're hiring! We are looking for a Research Assistant with protein biochemistry skills to develop novel protein-based immunotherapeutics targeting Treg cells in cancer. You'll join @roychoudhurilab.bsky.social @campathology.bsky.social @crukcamcentre.bsky.social Apply: jobs.cam.ac.uk/job/53219/

Interesting how companies and the financial world is racing to spend mindboggling amounts of money to build the infrastructure to train computers. But we are leaving the infrastructure to train and educate humans crumbling. The question is who will train who?

a man in a suit is holding a jacket and a cigarette .

ALT: a man in a suit is holding a jacket and a cigarette .

media.tenor.com

A more consistently warm home, no damp on the walls in winter and much cheaper heating

Ariana Bellucci@arianabellucci.bsky.social · 10mo ago

Love seeing people embrace greener heating. what’s been the biggest benefit for your home so far?